Eisai has made available Lusedra (fospropofol disodium injection), an intravenous water-soluble prodrug of the sedative-hypnotic agent propofol, for monitored anesthesia care (MAC) sedation in adult patients undergoing diagnostic or therapeutic procedures. Lusedra is only approved for use by persons trained in the administration of general anesthesia.
There are two dosing regimens for Lusedra: standard or modified. The standard dosing regimen is for patients 18 to <65 years of age who are healthy or have mild systemic disease. The modified dosing regimen is for patients ≥65 years of age or have severe systemic disease.
Lusedra is a C-IV controlled substance.
For more information call (888) 422-4743 or visit www.eisai.com.